Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Int J Radiat Oncol Biol Phys ; 116(2): 448-458, 2023 06 01.
Article in English | MEDLINE | ID: mdl-36549348

ABSTRACT

PURPOSE: Latin America faces a shortage in radiation therapy (RT) units and qualified personnel for timely and high-quality treatment of patients with cancer. Investing in equitable and inclusive access to RT over the next decade would prevent thousands of deaths. Measuring the investment gap and payoff is necessary for stakeholder discussions and capacity planning efforts. METHODS AND MATERIALS: Data were collected from the International Atomic Energy Agency's Directory of Radiotherapy Centers, industry stakeholders, and individual surveys sent to national scientific societies. Nationwide data on available devices and personnel were compiled. The 10 most common cancers in 2020 with RT indication and their respective incidence rates were considered for gap calculations. The gross 2-year financial return on investment was calculated based on an average monthly salary across Latin America. A 10-year cost projection was calculated according to the estimated population dynamics for the period until 2030. RESULTS: Eleven countries were included in the study, accounting for 557,213,447 people in 2020 and 561 RT facilities. Approximately 1,065,684 new cancer cases were diagnosed, and a mean density of 768,469 (standard deviation ±392,778) people per available unit was found. By projecting the currently available treatment fractions to determine those required in 2030, it was found that 62.3% and 130.8% increases in external beam RT and brachytherapy units are needed from the baseline, respectively. An overall regional investment of approximately United States (US) $349,650,480 in 2020 would have covered the existing demand. An investment of US $872,889,949 will be necessary by 2030, with the expectation of a 2-year posttreatment gross return on investment of more than US $2.1 billion from patients treated in 2030 only. CONCLUSIONS: Investment in RT services is lagging in Latin America in terms of the population's needs. An accelerated outlay could save additional lives during the next decade, create a self-sustaining system, and reduce region-wide inequities in cancer care access. Cash flow analyses are warranted to tailor precise national-level intervention strategies.


Subject(s)
Brachytherapy , Neoplasms , Radiation Oncology , Humans , Latin America/epidemiology , Neoplasms/radiotherapy , Investments
2.
Front Oncol ; 12: 850351, 2022.
Article in English | MEDLINE | ID: mdl-35371998

ABSTRACT

Purpose: The purpose of this study was to assess the effectivity of upfront kilovoltage intraoperative radiotherapy (IORT) as a boost in high-risk early-stage breast cancer patients from an international pooled cohort. Materials/Methods: Patients from four centers in three different countries were retrospectively screened. Those with a minimum 1-year follow-up were included. Cumulative local (LR), regional (RR), and distant metastasis rates (DM) were analyzed. Additionally, the estimated overall survival (OS) was assessed. The Cox regression analysis was performed to identify failure predicting factors. Results: A total of 653 patients from centers in Peru, Spain, and Germany were included. The median follow-up was 55 (12-180) months, and age was 58 (27-86) years. Clinical tumor (T) staging was T1 65.85%, T2 30.17%, and T3 3.98%. Positive margins were found in 7.9% and in-situ component in 20.06%. The median IORT dose was 20 (6-20). The median time from IORT to EBRT was 74.5 (13-364) days. An overall 3.4% (n = 22) of patients developed local recurrence at some point during follow-up. The 12-, 60-, and 120-month cumulative LR were 0.3%, 2.3%, and 7.9%, respectively. After multivariate analysis, only age <50 remained to be a significant prognostic factor for local recurrence (HR 0.19, 95% CI 0.08-0.47; p < 0.05). The 10-year estimated OS was 81.2%. Conclusion: Upfront boost with IORT yields similar local control outcomes to those EBRT-based reports. Results from prospective trials, regarding toxicity, cosmesis, and effectivity are awaited to confirm these findings.

3.
Radiol Case Rep ; 16(10): 3044-3050, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34306276

ABSTRACT

Hypercoagulability related to SARS-CoV-2 infection is one of the main extrapulmonary complications of COVID-19. We present three cases of intrabdominal thrombotic complications related to the state of hypercoagulability of COVID-19 and its tomographic features. Hypercoagulability state should be taking into account in the interpretation of radiological images in all infected patients with COVID-19.

4.
Ecancermedicalscience ; 15: 1336, 2021.
Article in English | MEDLINE | ID: mdl-35211205

ABSTRACT

BACKGROUND: There is a large gap in the data on cancer outcomes in Latin America, making it difficult to establish adequate cancer control policies in the region. The aim of our study was to describe the survival, life expectancy estimates and life expectancy changes over time for a large cohort of Peruvian patients insured with Oncosalud, a private healthcare system. PATIENTS AND METHODS: We evaluated a retrospective cohort of patients diagnosed between 2000 and 2015 in Oncosalud (Lima-Peru). Cases included colon, rectum, stomach, bladder, breast, prostate and non-melanoma skin cancers. Survival was evaluated with the Kaplan-Meier methodology. The standard period life table was used to estimate the excess mortality risks of patients in our cohort compared to the population covered by the Peruvian Superintendence of Banks, Insurance Companies and Pension Funds (SBS). The years of life lost was estimated based on SBS population, matching patients by age and sex. RESULTS: A large cohort of 7,687 Peruvian cancer patients managed in a 15-year period was eligible. If patients survive 5 years after a cancer diagnosis, life expectancy tends to be close to that of a population without cancer. The number of years of life lost at diagnosis was higher at the youngest ages, steadily decreasing thereafter. During the first years after cancer diagnosis, young patients face a much higher loss in life expectancy than older ones. Patients suffering from colon, rectum, stomach and bladder cancer are the most affected by the years of life lost. CONCLUSION: In cancer patients surviving ≥ 5 years, life expectancy becomes similar to that observed in a population with similar socioeconomic characteristics. The estimated survival rate in our cohort is higher than that reported by public cancer registries in Peru. This could be explained by the different socio-economic background and access to specialised cancer care.

5.
Crit Rev Oncol Hematol ; 157: 103129, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33227573

ABSTRACT

COVID-19 pandemic is the more challenging public health emergency of the century, producing the collapse of health systems and unprecedented levels of morbidity and mortality around the world, especially in low resource settings. Patients with chronic diseases are the most affected, not only due to the high susceptibility to SARS-CoV-2 infection but also due to the decrease in opportunities for timely care. In this dark landscape, telemedicine, before limited to very specific scenarios, has become one of our main tools to manage cancer patients, particularly in Latin America where COVID-19 has had a strong impact on the public health. Telemedicine can provide rapid access to specialized cancer care in a scenario complicated, reducing the exposure of patients and healthcare personnel to the SARS-CoV-2. In this review, we would like to share our experience and our workflow using telemedicine at Oncosalud-AUNA, a private clinic in Peru.


Subject(s)
COVID-19 , Telemedicine , Humans , Pandemics , Peru/epidemiology , SARS-CoV-2
6.
Strahlenther Onkol ; 196(12): 1086-1093, 2020 12.
Article in English | MEDLINE | ID: mdl-32816059

ABSTRACT

BACKGROUND: The COVID-19 pandemic outbreak has set the emergency services in developing countries on major alert, as the installed response capacities are easily overwhelmed by the constantly increasing high demand. The deficit of intensive care unit beds and ventilators in countries like Peru is forcing practitioners to seek preventive or early interventional strategies to prevent saturating these chronically neglected facilities. CASE PRESENTATION: A 64-year-old patient is reported after presenting with COVID-19 pneumonia and rapidly progressing to deteriorated ventilatory function. Compassionate treatment with a single 1­Gy dose to the bilateral whole-lung volume was administered, with gradual daily improvement of ventilatory function and decrease in serum inflammatory markers and oxygen support needs, including intubation. No treatment-related toxicity developed. Procedures of transport, disinfection, and treatment planning and delivery are described. CONCLUSION: Whole-lung low-dose radiotherapy seems to be a promising approach for avoiding or delaying invasive respiratory support. Delivered low doses are far from meeting toxicity ranges. On-going prospective trials will elucidate the effectiveness of this approach.


Subject(s)
COVID-19 Drug Treatment , COVID-19/radiotherapy , Anti-Bacterial Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/therapeutic use , Antiviral Agents/therapeutic use , COVID-19/blood , COVID-19/diagnostic imaging , COVID-19/therapy , Combined Modality Therapy , Compassionate Use Trials , Enoxaparin/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Male , Middle Aged , Oxygen Inhalation Therapy , Peru , Radiotherapy Planning, Computer-Assisted , Thrombophilia/drug therapy , Thrombophilia/etiology , Tomography, X-Ray Computed
7.
Ecancermedicalscience ; 13: 897, 2019.
Article in English | MEDLINE | ID: mdl-30792814

ABSTRACT

Breast cancer (BC) is a highly prevalent malignancy in Latin American women, most cases being diagnosed at locally advanced or metastatic stages when options for cancer care are limited. Despite its label as a public health problem in the region, Latin American BC patients face several barriers in accessing standard of care treatment when compared with patients from developed countries. In this review, we analyse the landscape of the four main identified barriers in the region: i) high burden of locally advanced/advanced BC; ii) inadequate access to medical resources; iii) deficient access to specialised cancer care and iv) insufficient BC research in Latin America. Unfortunately, these barriers represent the main factors associated with the BC poor outcomes seen in the region. Targeted actions should be conducted independently by each country and as a region to overcome these limitations and create an enhanced model of BC care.

9.
Ecancermedicalscience ; 11: 784, 2017.
Article in English | MEDLINE | ID: mdl-29225691

ABSTRACT

Radiotherapy was the first nonsurgical treatment for malignant tumours and represents one of the oldest disciplines of oncology. In Latin America, as in many parts of the world, the history of modern oncology begins with the implementation of radiation therapy facilities. The development of radiotherapy in Latin America was possible thanks to the seminal work of radiation oncologists in different countries. As a large territory, there is a need to implement modern facilities and equipment, but unfortunately there are disparities in the access and quality of radiotherapy services across Latin America and even within individual countries. In this review, we describe the history, challenges and success in the implementation of radiotherapy and the frustration caused by the lack of facilities in several Latin American countries.

10.
Mol Clin Oncol ; 5(2): 241-245, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27446557

ABSTRACT

Cervical cancer is the leading malignant neoplasm in Peruvian women. This malignancy is a public health problem and several efforts were previously performed to develop cancer control plans. Geographical, cultural, structural, infrastructural and procedural barriers can limit the implementation of such strategies. Several previous studies have characterized human papilloma virus (HPV) epidemiology, where prevalence of high-risk HPV in adult females is ~12% and the prevalence in cervical cancer is 90-95%. The predominant barriers for the control of cervical cancer are lack of specialists in remote villages, education/cultural issues, loss of patients in follow-up, lack of access to HPV testing and lack of compliance for HPV vaccination. A good strategy for the prevention and early detection of high-risk HPV, pre-malignant neoplasms and cervical cancer, identified by interventional studies, is the self-sampling test, which assists with overcoming the cultural and geographic barriers. The current cancer control plan, termed 'Plan Esperanza', is performed with massive training of health professionals and social sensitization campaigns leading to filling the gaps regarding education and, in addition, it provides cancer care coverage for poorer individuals. In our experience at Oncosalud-AUNA, with a cohort of ~750,000 affiliates using a pre-paid system with annual screenings for cervical cancer for women, offered free-of-charge, a lower incidence of this malignancy (5.8/100,000) is now observed compared with the national incidence (32.7/100,000). As in other countries, the HPV vaccination can be a cost-utility strategy to reduce the high burdens of cervical cancer in Peru, a rapid and cheap HPV molecular sub-typification is rapidly required.

11.
Oncotarget ; 7(15): 20282-92, 2016 Apr 12.
Article in English | MEDLINE | ID: mdl-26958810

ABSTRACT

There are different biological and clinical patterns of lung cancer between genders indicating intrinsic differences leading to increased sensitivity to cigarette smoke-induced DNA damage, mutational patterns of KRAS and better clinical outcomes in women while differences between genders at gene-expression levels was not previously reported. Here we show an enrichment of immune genes in NSCLC in women compared to men. We found in a GSEA analysis (by biological processes annotated from Gene Ontology) of six public datasets a repeated observation of immune gene sets enrichment in women. "Immune system process", "immune response", "defense response", "cellular defense response" and "regulation of immune system process" were the gene sets most over-represented while APOBEC3G, APOBEC3F, LAT, CD1D and CCL5 represented the top-five core genes. Characterization of immune cell composition with the platform CIBERSORT showed no differences between genders; however, there were differences when tumor tissues were compared to normal tissues. Our results suggest different immune responses in NSCLC between genders that could be related with the different clinical outcome.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Lung Neoplasms/genetics , Carcinoma, Non-Small-Cell Lung/immunology , Female , Humans , Lung Neoplasms/immunology , Male
13.
Brachytherapy ; 10(5): 363-8, 2011.
Article in English | MEDLINE | ID: mdl-21296032

ABSTRACT

PURPOSE: Relatively little is known about available resources and patterns of practice for brachytherapy (BT) in Latin America. To rectify this situation, we performed a patterns-of-care survey whose aim was to assess the human and material resources available for BT in Latin America and document current clinical practices. METHODS AND MATERIALS: A total of 392 radiotherapy (RT) centers located in 17 Latin American countries were asked to complete an online survey that included detailed questions about BT practices, facilities, and staffing. The study was coordinated through central offices located in Spain and Peru. National coordinators were appointed to manage the survey in each individual country. RESULTS: Overall, 77 of the 392 institutions (20%) completed the questionnaire. Of the 14 countries with at least one response, the participation rate was 35% (77 of 223 RT centers). The average number of patients (RT+BT) per center was 917. The mean number of BT patients per center increased by 46% (from 105 to 153 patients) from 2002 to 2007. Gynecologic localizations (endometrium, cervix, and vagina) accounted for 95% of treatments, and the uterine cervix was the most common tumor site (75% of all treatments). CONCLUSIONS: In Latin America, BT is most commonly used to treat gynecologic tumors, particularly of the cervix. Relatively few interventions were performed for breast and prostate. This was the first study of its kind in this region and should be repeated periodically.


Subject(s)
Brachytherapy/statistics & numerical data , Genital Neoplasms, Female/radiotherapy , Female , Health Care Surveys , Humans , Latin America , Personnel Staffing and Scheduling , Workload
14.
Radiother Oncol ; 71(3): 347-55, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15172152

ABSTRACT

BACKGROUND AND PURPOSE: Decisions in planning radiotherapy facilities in countries with limited financial resources require information on economic factors to make provision for sustainability. This study aims at acquiring data on some of these factors involved in delivery of teletherapy in 11 countries of different economic status. PATIENTS AND METHODS: Representatives of three European, one African, three Latin American and four Asian countries, were identified from radiation oncology institutions that operated both cobalt and linac teletherapy machines. Productivity data were prospectively collected for the year 2002. A detailed log was recorded for each machine over an arbitrary two-week period. Data on quality assurance (QA), maintenance, the capital costs of each machine, and the source replacement costs for the cobalt units were also recorded. RESULTS: Both linear accelerators and cobalt machines treat more than 10,000 fractions per year per machine with 2.5 and 2.3 fields per fraction, respectively. The capital costs of the machines vary considerably, with a factor of more than 10 for linear accelerators. Cobalt sources show a huge variation in price. The median costs of QA and maintenance of a linac was US$ 41,000 compared to US$ 6000 for cobalt machines. This results for the economic factors considered in median costs per fraction of US$ 11.02 for linear accelerators and US$ 4.87 for cobalt machines. These figures do not include the costs for physicians. CONCLUSIONS: The variation of the costs per fraction is more due to the result of differences in machine usage and costs of equipment than of national economic status. A treatment fraction on a linac with functionality comparable to cobalt, costs 50% more than cobalt therapy. This project shows that it is possible to collect data on economic factors prospectively as well as retrospectively.


Subject(s)
Developing Countries/economics , Particle Accelerators/economics , Radioisotope Teletherapy/economics , Capital Expenditures , Costs and Cost Analysis/economics , Economics , Maintenance/economics , Models, Econometric , Technology Assessment, Biomedical
15.
Radiother Oncol ; 64(3): 297-308, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12242118

ABSTRACT

PURPOSE: To provide recommendations for the implementation of high dose rate (HDR) 192Ir brachytherapy technology in developing countries. METHODS: An Advisory Group Meeting of the International Atomic Energy Agency (IAEA) met to address the implementation of HDR 192Ir brachytherapy technology in developing countries. These recommendations reflect only the personal opinions of the authors and do not necessarily represent the opinion of the IAEA. RESULTS: An HDR treatment system should be purchased as a complete unit that includes the 192Ir radioactive source, source loading unit, applicators, treatment planning system, and control console. Infrastructure support may require additional or improved buildings and procurement of or access to new imaging facilities. A supportive budget is needed for quarterly source replacement and the annual maintenance necessary to keep the system operational. The radiation oncologist, medical physicist, and technologist should be specially trained before HDR can be introduced. Training for the oncologist and medical physicist is an ongoing process as new techniques or sites of treatment are introduced. Procedures for quality assurance (QA) of patient treatment, and the planning system must be introduced. Emergency procedures with adequate training of all associated personnel must be in place. CONCLUSIONS: The decision to select HDR in preference to alternate methods of brachytherapy is influenced by the ability of the machine to treat a wide variety of clinical sites. In departments with personnel and budgetary resources to support this equipment appropriately, economic advantage becomes evident only if large numbers of patients are treated. Intangible benefits of source safety, personnel safety, and easy adaptation to fluctuating demand for treatments also require consideration when evaluating the need to introduce this treatment system.


Subject(s)
Brachytherapy , Health Plan Implementation , Iridium Radioisotopes/therapeutic use , Brachytherapy/economics , Brachytherapy/instrumentation , Brachytherapy/methods , Cobalt Radioisotopes/therapeutic use , Costs and Cost Analysis , Developing Countries , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Esophageal Neoplasms/radiotherapy , Female , Head and Neck Neoplasms/radiotherapy , Humans , International Agencies , Lung Neoplasms/radiotherapy , Male , Nuclear Energy , Radiotherapy Dosage , Uterine Cervical Neoplasms/radiotherapy
16.
Acta cancerol ; 25(1): 7-12, mar. 1995. ilus
Article in Spanish | LILACS, LIPECS | ID: lil-177916

ABSTRACT

El cáncer de cuello uterino es la neoplasia más frecuente en la mujer peruana y representa uno de los principales problemas de salud pública en nuestro medio. La causa del cáncer de cuello uterino es considerada multifactorial, siendo la edad temprana de la primera relación sexual y la poliandria, reportadas como los factores de riesgo más importantes. Entre enero de 1988 y julio de 1990 en el Departamento de Detección y Diagnóstico, del Instituto Nacional de Enfermedades Neoplásicas se diseñó un estudio de casos y controles, con la finalidad de determinar el perfil del riesgo de cáncer de cuello uterino de la mujer peruana. Se estudió 644 personas: 161 parejas casos y 161 parejas controles, con la finalidad de evaluar los factores de riesgo de cáncer de cuello uterino, analizándose edad, vida sexual, alimentación, higiene sexual, hábitos, uso de anticonceptivos, antecedentes de Papanicolau y enfermedades venéreas previas, entre otros factores. Los datos se analizaron usando un modelo de "regresión logística multivariante" para un estudio de caso-control. Al inicio del análisis hubieron 27 variables para los hombres y 17 para las mujeres, habiéndose reducido el número de ellas -sin perder información- al emplearse un análisis de "componentes principales". "La regresión logística multivariante" estableció que los factores de riesgo más importantes fueron: abortos antes del primer parto (APP), número de gestaciones (NGES), edad de la primera relación sexual de la mujer (EPRS), uso del preservativo por parte del hombre (PRESERV), edad de la menarquia (MENR) y número de abortos (ABORT). Para estos factores se obtuvieron los ODDS RATIOS siguientes: a) No uso de preservativo. OR:4.938 (IC 95 por ciento, 1.82-13.39); b) APP,OR: 2.815 (IC 95 por ciento, 1.25-6.29); c) EPRS, OR:2.483 (IC 95 por ciento, 1.564-3.94) y NGES. OR, 1.945 (IC 95 por ciento, 1.20-3.13). Los resultados del presente estudio sugieren que el cáncer de cuello uterino puede ser una enfermedad de transmisión sexual


Subject(s)
Humans , Male , Female , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/etiology , Peru/epidemiology , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...